Price (delayed)
$10.66
Market cap
$1.72B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$1.79B
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs
There are no recent dividends present for CERT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.